Abstract. IFN-inducible protein-10 (IP-10/CXCL10) is a potent chemoattractant for activated T lymphocytes and was recently reported to have several additional biologic activities. In this study, the expression and the function in normal glomeruli and in Thy1
IP-10, the blocking study was carried out with monoclonal anti-IP-10 antibody. The monoclonal anti-IP-10 antibody treatment decreased the expression of IP-10 and podocyteassociated proteins such as nephrin and podocin that are reported to be essential for maintaining the podocyte function (IP-10, 53.0% to control; nephrin, 43.5%; podocin, 60.4%). The findings indicated that the anti-IP-10 treatment disturbed the podocyte function. The anti-IP-10 treatment given to the rats with Thy1.1 nephritis exacerbated proteinuria, mesangiolysis, and matrix expansion. Collectively, the findings indicated that IP-10 plays a role in maintaining the podocyte function. Also, the findings suggested that anti-IP-10 treatment exacerbated the glomerular alterations in Thy1.1 GN by disturbing the podocyte function.
IFN-inducible protein of 10 kD (IP-10/CXCL10) identified as a product of genes induced in response to IFN-␥ is a member of the CXC chemokine family (1) . IP-10 is a potent chemoattractant for activated T lymphocytes, natural killer (NK) cells, and monocytes (2) and is believed to be a regulator of the type 1 T helper (Th1) inflammatory responses (3) . Recent studies indicated that the expression of IP-10 was observed in a variety of cells (4 -8) , and IP-10 had several additional biologic activities such as the stimulation of monocytes and lymphocytes, modulation of the adhesion molecule expression, and inhibition of angiogenesis (9) . It is reported that the expression of IP-10 was elevated in several diseases such as colitis, hepatitis, and multiple sclerosis and that IP-10 was involved in the development of these diseases (6,10 -12) . Romagnani et al. and other groups (13) (14) (15) (16) have reported that IP-10 was expressed in mesangial cells. Gomez-Chiarri et al. (17) reported that mRNA expression was detected in the cultured glomerular epithelial cells treated with adriamycin. Some studies with experimental model suggested that IP-10 contributed to the development of the glomerular diseases (13, (17) (18) (19) (20) . However, the knowledge on the expression and the function of IP-10 in glomeruli is still limited. Mesangial proliferative glomerulonephritis (GN) including IgA nephropathy is one of the most important diseases in the nephrology field. Anti-Thy1.1 antibody-induced GN (Thy1.1 GN) is most commonly used as a model of mesangial proliferative GN (21) . However, no precise studies of the role of IP-10 on the pathogenesis of Thy1.1 GN are reported.
In this study, first, an intense investigation was carried out on the expression and the function of IP-10 in normal rat glomeruli. Second, the expression and the role of IP-10 in Thy1.1 GN were studied. This study clearly showed that IP-10 is expressed on the podocyte and plays a role in maintaining the podocyte function. It was also demonstrated that the treatment of blocking anti-IP-10 mAb exacerbated the glomerular alteration in Thy1.1 GN.
Materials and Methods

Animal
All experiments were performed using specific pathogen-free female Wistar rats (6 wk old) that weighed 140 to 180g, purchased from Charles River Japan (Atsugi, Japan). All animal experiments conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Culture of Podocyte
Cultivation of conditionally immortalized mouse podocytes was conducted as reported previously (22) . In brief, podocytes were maintained in RPMI 1640 medium (Nissui Pharmaceutical, Tokyo, Japan) supplemented with 10% FBS (Life Technologies, Grand Island, NY), 100 U/ml penicillin (Banyu Pharmaceutical, Tokyo, Japan), and 0.1 mg/ml streptomycin (Meiji Seika Kaisha, Tokyo, Japan). To propagate podocytes, we cultivated cells at 33°C (permissive conditions), and the culture medium was supplemented with 10 U/ml mouse rIFN-␥ (Pepro Tech EC, England) to enhance expression of a thermosensitive T-antigen. To induce differentiation, we maintained podocytes at 37°C without IFN-␥ (nonpermissive conditions) for at least 1 wk before using in the experiment.
Experimental Design
Expression and Localization of IP-10 and CXCR3 in Normal Rat Glomeruli and in Cultured Podocyte. The expressions of IP-10 and CXCR3 for normal rat glomeruli and cultured podocyte were analyzed by immunofluorescence (IF) study and by Western blot techniques with two anti-IP-10 antibodies. mRNA expression of IP-10 was analyzed by reverse transcriptase-PCR (RT-PCR) with total RNA prepared from isolated glomeruli.
IP-10 Blocking Study in Normal Rat and Cultured Podocyte. In vivo IP-10 blocking was induced by injections of the anti-IP-10 mAb. This reagent was obtained by immunizing mice with rat CXCL10/Fc fusion protein, and then screened by measuring the binding to the rat CXCL10/Ac2A fusion protein (23) . It was already confirmed that this mAb blocked the rat CXCL10-induced chemoattractive effect (24) . As a control, mouse IgG1 mAb RVG1 (against rotavirus) was used. The blocking study was carried out according to two different concentrations of the anti-IP-10 mAb, such as 1 mg/100 g body wt as a low-dose injection and 5 mg/100 g body wt as a high-dose injection. Five rats received an injection of the anti-IP-10 mAb of each concentration intravenously daily for 5 d and were killed, and the right kidney was removed, weighed, cut into portions, and used for assessment of IF and light microscopy (LM). The remaining portion of right kidney and the left kidney were used to prepare the total glomerular RNA. mRNA expression of IP-10, nephrin, podocin, and podoplanin was analyzed by the semiquantitative RT-PCR on isolated glomeruli of pooled kidneys from five rats. Twenty-four-hour urine samples were collected just before the rats were killed. Urine protein concentrations were determined by the colorimetric assay (Bio-Rad, Oakland, CA) using BSA as a standard.
For analyzing the effect of anti-IP-10 mAb treatment on the expression of podocyte-associated molecules, immortalized cultured podocyte maintained at 37°C was incubated with anti-IP-10 mAb (1 mg/ml), RVG1 (1 mg/ml), or rabbit anti-podocalyxin antibody (100 mg/ml) for 24 h. mRNA expression of IP-10, nephrin, podocin, and podoplanin was analyzed by semiquantitative RT-PCR.
Expression of IP-10 and CXCR3 in Thy1.1 GN. Thy1.1 GN was induced in rats by a single injection with 1.0 ml of saline containing 500 g of anti-Thy1.1 mAb 1-22-3 through tail vein. Preparation of mAb 1-22-3 and induction of Thy1.1 GN have been 5Ј   3Ј   5Ј   3Ј   IP-10  TGT CGT TCT CTG CCT CGT GCT   GAC CTT CTT TGG CTC ACC GCT   58   264   NM139089   IP-10   b   CCG TCA TTT TCT GCC TCA TCC   GAC CTT TTT TGG CTA AAC GCT TTC   56   265   AF227743   CXCR3   c   GCT GTG GCC GAT GTA CTG CTG G   CCA GGT GAT AGG GGG TCC and differentiated (37°C) immortalized podocytes. As a positive control, IP-10 and CXCR3 were also amplified from mouse spleen cDNA. The expression of mRNA for IP-10 was seen in both undifferentiated and differentiated conditioned podocytes. The expression of mRNA for CXCR3 was seen in differentiated conditioned podocyte, but no expression was detected in undifferentiated conditioned podocyte. (C) Western described previously (25) . The rats were killed just before injection of mAb 1-22-3 and on days 1, 5, and 14 after induction of GN (n ϭ 5 per time point). At each time point, a rat was killed and the kidney was treated as described above. The kinetics of the expression of IP-10 and CXCR3 were analyzed by IF and RT-PCR. To investigate the localization of IP-10 and CXCR3, dual-labeling staining was carried out with several cellular markers including leukocyte common antigen, monocyte/macrophage marker, CD5, RECA-1, ␣-smooth muscle actin (␣-SMA), and podocalyxin. IP-10 Blocking Study in Thy1.1 GN. Thy1.1 GN was caused in rats by mAb 1-22-3 in the same manner described above. The rats with Thy1.1 GN were treated with anti-IP-10 mAb at 5 h after mAb 1-22-3 injection and treated daily until the day of killing. The rats were killed on day 5 and day 14 (n ϭ 5 per group), and kidneys were removed as described above. Twenty-four-hour urine samples were collected on days 1, 3, 5, 7, 10, and 14 after injection of mAb 1-22-3. Urine protein concentrations were determined as described above. Glomerular injury was assessed by LM and IF. The severity of morphologic alterations was evaluated in a double-blind manner with Ͼ30 full-sized glomeruli (80 to 100 m) from each specimen. The severity of mesangiolysis, mesangial matrix expansion, and the intensity of ␣-SMA staining were scored as described previously by Ito et al. (21) . To analyze whether inflammatory responses are affected by the anti-IP-10 mAb treatment, we counted the number of OX-1-, ED1-, and OX-19 -positive inflammatory cells in glomeruli. The expression of nephrin, podocin, and podoplanin was analyzed by immunofluorescence. Glomerular mRNA expression for podocyteassociated molecules was analyzed by RT-PCR. In this study, the expression for nephrin, podocin, and podoplanin to that of podocalyxin was calculated. Considering the mesangial proliferation of Thy1.1 GN, podocalyxin is more proper than GAPDH for internal control of mRNA of podocyte, because podocalyxin is thought to be a stable molecule in podocyte from our experience. Glomerular mRNA expressions for chemokine (IP-10, macrophage-derived chemokine [MDC]), chemokine receptor (CXCR3), and cytokine (IFN-␥, IL-4) were also analyzed by RT-PCR.
Localization of Anti-IP-10 mAb Injected into Normal and Thy1.1 GN Rats
Normal rats or the rats 5 d after induction of Thy1.1. GN received an intravenous injection of 5 mg/100 g body wt anti-IP-10 mAb or RVG1 and were killed 10 min after the injection. To detect the anti-IP-10 mAb injected to rat, we used goat anti-mouse IgG1 as a primary antibody and FITC-conjugated anti-goat IgG as a secondary antibody.
Morphologic and Immunohistochemical Studies
Tissue samples for LM assessment and for the IF studies were prepared as described previously (21) . The 3-m-thick frozen sections were cut with a cryostat and stained with goat anti-IP-10 antibody (Santa Cruz Biotechnology), goat anti-CXCR3 antibody (Santa Cruz Biotechnology), rabbit anti-nephrin antibody (intracellular site) (26), rabbit anti-podocin antibody (N-terminal site) (27) , and rabbit antipodoplanin antibody (28) . The double-staining IF for anti-IP-10 and anti-CXCR3 was performed with several cellular markers such as OX-1 (leukocyte marker), ␣-SMA (as an injured mesangial cell marker), RECA-1 (as endothelial cell marker), podocalyxin (as podocyte marker), CD5 (as a T-cell marker), and ED1 (as a pan monocyte/ macrophage marker). Anti-leukocyte common antigen mAb (OX-1), anti-RECA-1 mAb, and anti-OX-19 mAb (anti-CD5) were purchased from Serotec (Oxford, JE, UK); anti-␣-SMA mAb was purchased from Sigma (St. Louis, MO); and anti-ED1 mAb was purchased from Chemicon Internation (Temecula, CA). Anti-podocalyxin antibody 4D5 was donated by Dr. Hara (Yoshida Hospital, Niigata, Japan). The clone producing 4D5 was purified from hybridoma cells fused with spleen cells from mice immunized with podocalyxin-rich fraction prepared with WGA-Sepharose 4B (29) . The specificity of 4D5 was analyzed with immunohistochemical studies, immunoprecipitation, and Western blot analysis using anti-podocalyxin mAb 5A as positive control (30) (5A was donated by Dr. Miettinen, University of Helsinki, Helsinki, Finland).
FITC-conjugated anti-goat IgG (for anti-IP-10 and anti-CXCR3 antibodies), tetramethyl-rhodamine isothiocyanate (TRITC)-conjugated goat anti-mouse IgG1 (for OX-1, anti-RECA-1, OX-19, and ED1 mAb), and TRITC-conjugated goat anti-mouse IgG2a (for anti-␣-SMA mAb and 4D5) were used as secondary antibodies. FITCconjugated goat anti-mouse IgG1 was used to count the number of OX-1-, OX-19 -, and ED1-positive cells. These secondary antibodies were purchased from Southern Biotechnology Associates (Birmingham, AL). FITC-conjugated swine anti-rabbit IgG was used for antinephrin, anti-podocin, and anti-podoplanin antibodies. This secondary antibody was purchased from DAKO (Glostrup, Denmark).
RT-PCR
Semiquantitative RT-PCR with glomerular RNA was performed basically according to the method described previously (21) . The primers were designed according to the published sequences (Table 1) . Negative controls without cDNA and positive controls of cDNA from Con-Astimulated rat spleen cells were included. 
Western Blot Analysis
Normal rat glomeruli and cultured podocyte were isolated with PBS containing protease inhibitors and solubilized with RIPA buffer (consisting of 0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100, 150 mmol/L NaCl, and 10 mmol/L EDTA in 25 mmol/L Tris-HCl [pH 7.2]) with protease inhibitors. The insoluble material was removed by centrifugation at 15,000 ϫ g for 10 min. The concentration was measured by the bicinchoninic acid method (Pierce Chemical, Rockford, IL), and the solubilized material was subjected to SDS-PAGE with 12% acrylamide gel according to the method of Laemmli et al. (31) and transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA) by electrophoretic transblotting for 30 min using Trans-Blot SD (Bio-Rad). After blocking with bovine skim milk, strips of the membranes were exposed to two kinds of anti-IP-10 antibodies; one is the goat anti-IP-10 antibody (Santa Cruz Biotechnology), and the other is the anti-IP-10 mAb from the mouse. They both were washed and then incubated with alkaline phosphatase-conjugated rabbit anti-goat IgG (Bio Source International, Tago Immunologicals, Camarillo, CA) or with alkaline phosphatase-conjugated anti-mouse IgG (Bio Source International, Tago Immunologicals). The reaction was developed with an alkaline phosphatase chromogen kit (5-bromo-4-chloro-3-indolil phosphate p-toluidine salt/nitro blue tetrazolium; Biomedica, Foster City, CA).
Statistical Analyses
All values are expressed as means Ϯ SD. The statistical significance (defined as P Ͻ 0.05) was evaluated using the unpaired t test or Mann Whitney U test. Data were analyzed using the GraphPad InStat 3.05 (GraphPad Software, San Diego, CA).
Results
IP-10 and CXCR3 Were Expressed in Normal Rat Glomeruli and Cultured Podocyte
IP-10 and CXCR3 expressions were detected in the normal rat glomeruli by IF study with goat anti-IP-10 and anti-CXCR3 antibodies, and no staining with normal goat serum was seen (Figure 1 , Panel I-A). Immunostaining of IP-10 was observed as a linear-like pattern along the glomerular capillary wall, and CXCR3 staining was also observed as an epithelial pattern along the glomerular capillary wall. IP-10 and CXCR3 expressions in normal rat glomeruli were also detected by RT-PCR (Figure 1, Panel I-B) . The Western blot analysis was performed with the goat anti-IP-10 antibody and the mouse anti-IP-10 mAb that was used for the IP-10 neutralization study. Approximately 10-kD bands of IP-10 were detected by both antibodies (Figure 1, Panel I-C, lanes 1 and 3) . No binding bands were detected by either normal goat serum or RVG1 (lanes 2 and 4) . 
Anti-IP-10 mAb Treatment Decreased the Expression of IP-10 and Podocyte-Associated Proteins
The effects of anti-IP-10 mAb treatment on the expression of glomerular IP-10 mRNA were shown in Figure 2 , Panel I. A high-dose treatment (5 mg/100 g body wt) clearly decreased the IP-10 expression, whereas there was no difference of IP-10 expression between the low-dose treatment (1 mg/100 g body wt) group and the RVG1 (5 mg/100 g body wt) treatment group. Neither abnormal proteinuria nor morphologic abnormality observed by LM was detected in the anti-IP-10 mAb treatment group. mRNA expressions for podocin, nephrin, and podoplanin were clearly decreased by the high-dose anti-IP-10 mAb treatment (Figure 2 positive inflammatory cells in glomeruli of the anti-IP-10 mAbtreated group was slightly higher than that of the RVG1 group; however, there was no statistical difference between the two groups on either day 5 or day 14 ( Figure 6 , Panel II-C and D). Mesangiolysis observed on day 5 and the extent of the ␣-SMA staining and mesangial matrix on day 14 were significantly exacerbated by the anti-IP-10 treatment (Figure 6 , Panel II-E, F, and H). Figure 7 shows representative findings of OX-1, mesangiolysis, mesangial matrix, and ␣-SMA staining. We also investigated the IF staining patterns of podocyte-associated proteins in glomeruli on day 5 and day 14. On day 5, more discontinuous staining of nephrin podocin and podoplanin were observed in the anti-IP-10 mAb treatment group than in the RVG1 control group (Figure 8) . On day 14, staining intensities of nephrin, podocin, and podoplanin were weaker in the anti-IP-10 mAb treatment group than in the RVG1 control group (Figure 9 ). The anti-IP-10 treatment clearly decreased the glomerular mRNA expression of nephrin, podocin, and podoplanin on day 5 after induction of Thy1.1 GN (Figure 10 ). Figure 11 shows the effect of anti-IP-10 mAb treatment on rat glomerular mRNA expression for several chemokines and cytokines on 5 d after Thy1.1 GN induction. Anti-IP-10 mAb treatment did not affect the mRNA expressions of IP-10, CXCR3, MDC, IL-4, and IFN-␥.
Injected Anti-IP-10 mAb Was Observed along the Capillary Loop
Anti-IP-10 mAb injected into normal rat was observed along the glomerular capillary loop ( Figure 12A ). Clear staining of anti-IP-10 as capillary loop pattern was observed in rats with Thy1.1 GN ( Figure 12B ). RVG1 injected into rat with Thy1.1 GN was not detected ( Figure 12C ).
Discussion
IP-10 and its receptor CXCR3 are reported to be expressed in a variety of cells (4 -8) . However, the expression and the function of IP-10/CXCR3 in glomeruli are poorly understood. Although the study with IP-10 -deficient mouse (32) was reported, there was no description of the disorder of kidney. In this study, we investigated whether and where IP-10 is expressed in normal glomeruli. The expression of IP-10 was detected in normal rat glomeruli by IF, RT-PCR, and Western blot analysis (Figure 1, Panel I) . Immunostaining of IP-10 was demonstrated as a linear-like pattern along the glomerular capillary loop, which suggested that IP-10 was expressed on the glomerular visceral epithelial cell (podocyte). We observed that IP-10 was expressed also in cultured podocyte in both undifferentiated and differentiated conditions (Figure 1 , Panel II). CXCR3 staining is also observed as an epithelial pattern along the glomerular capillary wall, and CXCR3 expression was detected in cultured podocyte at differentiated condition. Podocyte is a highly differentiated cell characterized by interdigitating foot processes covering glomerular basement membrane and is accepted to play an important role to keep the normal permselectivity of the glomerular capillary wall. Recently, podocyte was reported to have a multi-role for maintaining the glomerular function (33, 34) . In 1996, GomezChiarri et al. (17) reported that mRNA expression of IP-10 was detected in the cultured glomerular epithelial cells treated with adriamycin. Recently, Huber et al. (35) reported that CXCR3 was expressed on podocyte and that CXCR3 may contribute to podocyte injury. Romagnani et al. (15) reported that IP-10 was expressed in podocyte in cases of human disease. However, few studies analyzing the expression and the function of IP-10/CXCR3 in podocyte with in vivo material are reported. In this study, we clearly demonstrated that IP-10/CXCR3 is expressed on podocyte. In the previous report with a murine acute colitis model, we demonstrated that IP-10 could directly inhibit the proliferation and migration of epithelial cell (36) . Chemokines generally have a capability to activate the adhesion molecules on various types of cells (37, 38) . It is reported that the expressions of integrin and cadherin mediated by IP-10 may contribute to firm cellular interactions with an adjacent cell and with extracellular matrix (36) . Although the function of IP-10 on podocyte is uncertain, we hypothesized that IP-10 contributes to maintaining the highly differentiated structure and the function of podocyte.
Next, to test the hypothesis, we analyzed the function of IP-10 expressed on podocyte by the blocking study. A mAb with blocking activity to IP-10 was prepared in mice by immunization with rat IP-10/Fc fusion protein (23) . The blocking activity of the anti-IP-10 mAb used in this study was confirmed in the chemotactic assay and in the study with the murine models of acute colitis (36) and encephalomyelitis (39) . We confirmed that the anti-IP-10 mAb has no cross-reactivity with other chemokines such as monokine induced by IFN-␥, macrophage inflammatory protein-1␣, and MDC (40) . To elucidate the effect of the anti-IP-10 mAb treatment on the podocyte, we analyzed the expression of IP-10 and the functional molecules of podocyte such as nephrin, podocin, and podoplanin. Nephrin (26, 41) and podocin (27, 42) are critical components of slit diaphragm that interacts adjacent foot processes and functions to maintain the barrier function of the glomerular capillary wall (43, 44) . Podoplanin is believed to be a critical molecule for maintaining the foot process structure of podocyte (45) . The glomerular expression of IP-10 and these functional molecules of podocyte were confirmed to be decreased by the treatment of anti-IP-10 mAb (Figure 2) . In this study, we showed that the anti-IP-10 mAb injected into normal rat specifically bound to the IP-10 expressed on podocyte ( Figure 12A ). The injected anti-IP-10 mAb comes across the glomerular basement membrane and acts on its target IP-10 expressed on the podocyte. This can explain why a relatively high dose of the anti-IP-10 treatment was necessary to affect the podocyte (Figure 2 ). The effects of anti-IP-10 mAb treatment observed in in vivo studies were also confirmed by in vitro study using cultured podocyte (Figure 3) . The next question that arose was whether the effect of anti-IP-10 is a specific one. Because our group has been producing some mAbs that recognize glomerular antigens (25, 44) , we have several mAbs with binding activity to rat podocyte. However, most of these mAbs have no biologic activity. We have experienced that these mAbs did not affect the expression of the functional molecules of podocyte, even when a large amount of antibody was injected into rats (data not shown). In the study with cultured podocyte, we showed that even the very high dose of anti-podocalyxin antibody treatment did not affect the expression for IP-10 or podocyte functional molecules. From these observations, it is conceivable that the specific intervention of IP-10 by anti-IP-10 mAb depressed the expression of the functional molecules of podocyte. The findings suggest that IP-10 plays a role for maintaining the podocyte function.
Next, we investigated the role of IP-10 on the pathogenesis of the glomerular disease. In this study, we adopted Thy1.1 GN. Although Thy1.1 GN is commonly used as a model of mesangial proliferative GN, which is one of the most important diseases in the nephrology field, no studies analyzing the role of IP-10 in Thy1.1. GN are reported. Another reason that we adopted Thy1.1 GN in this study is that we previously reported that podocyte dysfunction was highly concerned with the prognosis of mesangial alterations (28) . We analyzed the kinetics of the expression of IP-10 during the development of Thy1.1 GN. Thy1.1 GN is characterized by mesangiolysis followed by inflammatory cell infiltration, mesangial cell proliferation, and the consequent mesangial matrix expansion. The elevated expression of IP-10 mRNA was already observed on day 1, and it peaked on day 5 after the induction of Thy1.1 GN, when the amount of urinary protein excretion peaked (Figure 4 Next, we further analyzed the role of IP-10 on the pathogenesis of Thy1.1 GN by blocking study with anti-IP-10 mAb. We demonstrated here that anti-IP-10 treatment increased the amount of proteinuria. It was also shown that the anti-IP-10 mAb treatment exacerbated the mesangial morphologic alterations (Figures 6 and 7) . It is thought that the exacerbated mesangiolysis in the early phase resulted in the increased ␣-SMA staining and the expansion of mesangial matrix in the following phase of Thy1.1 GN. For the explanation of the mechanism of the exacerbation of Thy1.1 GN, first we have to mention that the IP-10 blockade modulated the inflammatory responses, because Th1 cytokines are considered to be involved in the development of Thy1.1 GN (46). However, there were no significant differences in numbers of OX-1-, ED1-or CD5-positive inflammatory cells between both groups ( Figure  6 , Panel II-A and B). Anti-IP-10 mAb treatment did not affect the expression of IFN-␥, MDC, or IL-4 in Thy1.1 GN ( Figure   11 ). In the previous studies in the experimental models of encephalomyelitis (39) and hepatitis (40), we reported that anti-IP-10 treatment did not affect the Th1/Th2 polarization. From these observations and the previous reports, we consider that the exacerbated glomerular alteration caused by the IP-10 blockade did not result from the modulated inflammatory response. Next, we should mention the possibility that mesangial cell damage caused by the anti-IP-10 treatment directly resulted in the exacerbated mesangial alterations. Romagnani et al. (15, 47) reported that IP-10 and CXCR3 are expressed in the mesangial cells. In this study, the increased expression of IP-10 in Thy1.1 GN was observed not only on the podocyte but also in the mesangial area. These findings suggest that the anti-IP-10 mAb treatment may directly exacerbate the mesangial injury in Thy1.1 GN. However, we showed here that IP-10 staining was observed as an epithelial pattern along the glomerular capillary wall in normal rat section and that an increased expression of IP-10 in Thy1.1 GN was mainly detected on the podocyte and that in the mesangial area was partly and weak. These findings suggested that the injected anti-IP-10 mAb mainly acts on podocyte. More discontinuous staining of nephrin, podocin, and podoplanin was observed in the anti-IP-10 treatment group of Thy1.1 GN than in RVG1 control group (Figure 8 ). We also observed that the anti-IP-10 treatment decreased the glomerular mRNA expression for nephrin, podocin, and podoplanin on day 5 after induction of Thy1.1 GN (Figure 10 , Panel I). It should be mentioned that anti-IP-10 treatment did not decrease the mRNA expression for IP-10 on day 5 of Thy1.1 GN, although the treatment in normal rats decreased IP-10 expression. We cannot give a clear explanation for these results. We consider that because mRNA expression for IP-10 clearly increased on day 5 of Thy1.1 GN ( Figure  4A ), the anti-IP-10 mAb treatment did not affect the mRNA expression for IP-10 at this time point of disease. However, we also observed that anti-IP-10 mAb injected into rat at 5 d of Thy1.1 GN was detected as a podocytic pattern along the capillary loop ( Figure 12B ). The finding also indicates that the injected anti-IP-10 mAb evidently acts on podocyte. We have previously demonstrated that the minor podocyte injury evaluated by the decreased expression of the functional molecules of podocyte could exacerbate the mesangial injury of Thy1.1 GN (28). Shih et al. (48) reported that mesangial cell proliferation and the matrix expansion were observed in the knockout mouse of CD2-associated protein, a component of slit diaphragm. It was discussed that the mesangial alterations in this mouse were brought on by the dysfunction of the podocyte. Taken together with these previous reports and all of the observations in this study, it is conceivable that the exacerbated proteinuria and mesangial alterations in Thy1.1 GN resulted from the podocyte dysfunction that was caused by IP-10 blockade.
In conclusion, IP-10 was expressed on normal glomerular podocyte, and these expressions were elevated in Thy1.1 GN. A receptor for IP-10, CXCR3, showed similar expression patterns to that of IP-10. IP-10 plays a role for maintaining the podocyte function. The blockade of IP-10 exacerbated the glomerular alterations in Thy1.1 GN probably by disturbing the podocyte function.
